{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:55:34Z","timestamp":1794858934040,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ijantimicag.2014.07.001","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T18:20:39Z","timestamp":1408558839000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections"],"prefix":"10.1016","volume":"44","author":[{"given":"S.","family":"Luque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alvarez-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Ferr\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Campillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Horcajada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Basas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"J.A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0005","series-title":"Sociedad Espa\u00f1ola de Medicina Intensiva, Cr\u00edtica y Unidades Coronarias (SEMICYUC), Grupo de Trabajo de Enfermedades Infecciosas","author":"Estudio Nacional de Vigilancia de Infecci\u00f3n Nosocomial en Servicios de Medicina Intensiva (ENVIN-HELICS)","year":"2012"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0010","series-title":"Protocols i procedimients d\u2019infermeria, Malalt neurocritic","author":"Hospital del Mar, Parc de Salut Mar","year":"2010"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/00365540110080467","article-title":"Linezolid for the treatment of central nervous system infections in neurosurgical patients","volume":"34","author":"Viale","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/AAC.46.3.936-937.2002","article-title":"Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections","volume":"46","author":"Villani","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12028-008-9155-y","article-title":"Management of nosocomial external ventricular drain-related ventriculomeningitis","volume":"10","author":"Beer","year":"2009","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00701-007-1458-9","article-title":"Risk factors for infections related to external ventricular drainage","volume":"150","author":"Hoefnagel","year":"2008","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0213-005X(08)72696-X","article-title":"Infection of cerebrospinal fluid shunt systems","volume":"26","author":"Jim\u00e9nez-Mej\u00edas","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1358\/dot.2000.36.9.593780","article-title":"Linezolid: a new antibiotic","volume":"36","author":"Xiong","year":"2000","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0045","first-page":"112","article-title":"Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds","volume":"13","author":"Sabbatani","year":"2005","journal-title":"Infez Med"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1331.2005.01001.x","article-title":"Clinical experience with linezolid for the treatment of central nervous system infections","volume":"12","author":"Rupprecht","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood\u2013cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0060","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/AAC.00051-06","article-title":"Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients","volume":"50","author":"Myrianthefs","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/AAC.00515-06","article-title":"Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains","volume":"51","author":"Beer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0070","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3109\/00365548.2011.582140","article-title":"Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics","volume":"43","author":"Viaggi","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0075","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3109\/00365548.2011.600327","article-title":"Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis","volume":"43","author":"Tsuji","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1179\/joc.2007.19.1.90","article-title":"Linezolid cerebrospinal fluid concentration in central nervous system infection","volume":"19","author":"Malacarne","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0085","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.2174\/138920111798808329","article-title":"Using PK\/PD to optimize antibiotic dosing for critically ill patients","volume":"12","author":"Roberts","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0090","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0100","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. \u3008http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/Breakpoint_table_v_4.0.pdf\u3009 [accessed 16 January 2014]."},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0105","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0110","series-title":"NONMEM 7.2.0 Users Guides","year":"1989"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0120","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0125","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1345\/aph.1H029","article-title":"Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis","volume":"40","author":"Boak","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0130","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1128\/AAC.01468-05","article-title":"Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis","volume":"50","author":"Buerger","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0135","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1124\/dmd.106.013755","article-title":"Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0140","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","article-title":"Risk factors for a low linezolid trough plasma concentration in acute infections","volume":"57","author":"Morata","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/CCM.0b013e31826ab4c4","article-title":"Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility","volume":"41","author":"Roberts","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.07.001_bib0150","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T07:58:46Z","timestamp":1538294326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0924857914002313"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}